Key Takeaways
- GIC and Temasek have acquired a significant stake in Novotech, with TPG also reinvesting, to fuel the company’s global expansion.
- Novotech aims to establish itself as a leading global biotech-focused CRO, leveraging growth opportunities in Asia, the US, and Europe.
- The investment will support Novotech’s ability to undertake larger, multi-region clinical trials and transformative acquisitions.
Novotech Secures Investment to Fuel Global Growth
Novotech, a prominent full-service clinical research organization (CRO) specializing in biotech, has announced a substantial investment from GIC and Temasek, alongside a reinvestment from existing owner TPG. This funding is intended to drive Novotech’s global expansion efforts as it seeks to establish itself as a preeminent biotech-focused CRO globally.
Based in Singapore, Novotech operates more than 30 offices worldwide, primarily across the Asia-Pacific region, North America, and Europe. The company is noted for its partnerships with over 5,000 clinical trial sites and its leadership in innovative research areas, including cell and gene therapies, radiopharmaceuticals, and mRNA trials.
Novotech’s CEO, John Moller, expressed enthusiasm regarding the new investment, highlighting the company’s capability to accelerate growth in the rapidly expanding clinical trial market in Asia, which is projected to grow at an annual rate of 15%. Moller affirmed that the support from GIC, Temasek, and TPG would enable Novotech to not only bolster its existing operations but also pursue larger-scale mergers and acquisitions as the industry consolidates.
After significant growth since TPG’s initial investment in 2017, Novotech has expanded from a 300-person team focused mainly in Australia and New Zealand to approximately 3,000 employees with a global footprint. Joel Thickins from TPG Asia recognized Novotech’s impressive performance and expressed commitment to supporting the company’s continued journey toward significant global expansion.
The healthcare investment strategy of TPG Asia underlines its focus on fruitful partnerships that yield long-term value. Along with Novotech, TPG holds substantial stakes in various healthcare entities across the Asia-Pacific region, demonstrating its confidence in the industry’s growth potential.
Choo Yong Cheen, GIC’s Chief Investment Officer for Private Equity, echoed support for Novotech, noting the company’s established record in providing high-quality outcomes for biopharmaceutical clients. He expressed optimism about contributing to Novotech’s future growth through both organic investment and strategic acquisitions.
The details of the investment transaction were not disclosed, but it is anticipated that the influx of capital will significantly enhance Novotech’s capabilities to successfully manage larger, complex clinical trials, particularly those centered in Asia.
By merging a client-centered approach with deep expertise in multiple therapeutic areas, Novotech continues to demonstrate its commitment to driving innovation and improving global health outcomes through clinical research. The company’s accolades, including numerous awards for excellence in clinical trial execution, further validate its leadership role in the sector.
The content above is a summary. For more details, see the source article.
